8-Week Pharmacokinetic & Receptor Occupancy Curve
Cross-Titration Pathway
Semaglutide Half-Life
7 Days
~168h albumin-bound clearance
Trough Occupancy
68%
Min. baseline GLP-1 binding
Week 4 Multi-Agonism
GLP-1 + GIP + GCGR
Triple incretin activation
Metabolic Adaptation & Energy Balance Diagnostic
24M | 172 lbs | 5'7"
172 lbs
1800 kcal
5 days
150 g
Plateau TDEE (Adapted)
2,140 kcal
BMR 1,720 - 150 kcal NEAT adaptation
Effective Deficit
340 kcal
At 1,800 kcal intake
Projected Rate
0.68 lbs/wk
Remaining to 155 lbs: ~25 wks
Why Max-Dose Wegovy (2.4mg) Stalls After 40 lbs:
As body mass decreased from 210 lbs to 172 lbs, maintenance expenditure dropped by ~380 kcal. Combined with GLP-1 receptor down-regulation and subtle metabolic adaptation, the previous 800 kcal deficit contracted to 340 kcal. A mere 200 kcal weekend tracking discrepancy completely neutralizes scale movement.
Visceral (VAT) vs. Subcutaneous (SAT) & GHRH Reality Check
Target Tissue Anatomy
Transition Economics & Clinical Dossier
Decision Matrix
| Protocol Pathway | Monthly Cost | Receptor Affinity | Tolerance Reset |
|---|---|---|---|
| Stay on Wegovy 2.4mg | $50 (Insurance) | GLP-1 Only (Saturated) | Zero (Ceiling Effect) |
| Cross-Titrate Retatrutide | $140 - $220 (OOP) | GLP-1 / GIP / GCGR | High (Glucagon Thermogenesis) |
| Bridge to Tirzepatide 5-7.5mg | $110 - $180 (OOP) | GLP-1 / GIP Dual | Moderate (GIP Satiety Synergy) |
| Add Tesamorelin (GHRH) | +$400 - $500/mo | GHRH -> IGF-1 (VAT Only) | Ineffective for Subcutaneous Fat |
Structured Physician Dossier Preview:
Loading dossier...